para />
Infants <3 months, consider vertical transmission
Children: fever, >50 lesions, limited response to therapy, consider immunodeficiency
Children: anogenital lesions, consider autoinoculation/possible sexual abuse
DIFFERENTIAL DIAGNOSIS
- AIDS patients: cryptococcus, penicilliosis, histoplasmosis, coccidioidomycosis
- Basal cell carcinoma
- Benign appendageal tumors: syringomas, hydrocystomas, ectopic sebaceous glands
- Condyloma acuminatum
- Dermatofibroma
- Eyelid: abscess, chalazion, foreign-body granuloma
- Folliculitis/furunculosis
- Keratoacanthoma
- Oral squamous cell carcinoma
- Trichoepithelioma
- Verruca vulgaris
- Warty dyskeratoma
DIAGNOSTIC TESTS & INTERPRETATION
Initial Tests (lab, imaging)
- Virus cannot be cultured.
- Culture lesion if concern is secondary infection
- Sexual transmission: Test for other sexually transmitted infections, including HIV.
- Microscopy: scrape lesion
- Core material has characteristic Henderson-Paterson intracytoplasmic viral inclusion bodies.
- Crush prep with 10% potassium hydroxide will show characteristic inclusion bodies as well.
- Alternatively, hematoxylin-eosin-stained formalin-fixed tissue shows same confirmatory features.
Diagnostic Procedures/Other
Clinical; using magnifying lens
Tests Interpretation
Molluscum cytoplasmic inclusion bodies within keratinocytes
TREATMENT
GENERAL MEASURES
- In healthy patients, molluscum contagiosum is generally self-limited and heals spontaneously.
- No single intervention is shown to be convincingly more effective than any other in treating molluscum contagiosum (1)[B].
- No treatment is FDA-approved for treatment of molluscum contagiosum.
- Three categories of treatment: destructive, immune-enhancing, and antiviral
MEDICATION
First Line
- Cantharidin 0.7 " 0.9% solution: In office application to lesions, cover with dressing; wash off in 2 to 6 hours or sooner if blistering. Repeat treatment every 2 to 4 weeks until lesions resolve (1)[B],(2,3)[C].
- Not commercially available in the United States but may be obtained from Canada
- Adverse effects: blistering, erythema, pain, pruritus
- Precautions: Do not use on face or on genital mucosa.
Second Line
- Benzoyl peroxide 10% cream: Apply to each lesion twice daily for 4 weeks (1)[B].
- Inexpensive
- Adverse effects: mild dermatitis
- For immunocompromised patients with refractory lesions, consider
- Starting or maximizing HAART therapy in patients with HIV/AIDS (4)[C]
- Cidofovir
- 3% cream applied to lesions once daily, 5 days/week for 8 weeks (4)[C]
- 1% cream applied to lesions once daily, 5 days/week for 2 weeks, repeat in 1 month, if necessary (4)[C]
- Adverse effects with topical use: erythema, pain, pruritus, erosions
- 3 to 5 mg/kg IV weekly for 1 to 2 weeks, followed by IV infusions every other week, until clinical clearance or up to 9 infusions (5)[C]
- Adverse effects with IV use: nephrotoxicity, neutropenia
- Monitoring with IV use: renal function and complete blood counts prior to and 24 to 48 hours after infusions
- Precaution: Must coadminister oral probenecid and provide IV hydration with each IV infusion; refer to cidofovir manufacturer 's recommendations on dosing.
- Ingenol mebutate 0.015% gel applied to lesions once daily for 3 days; may repeat once if needed (6)[C] very expensive
- Adverse effects: erythema, irritation
SURGERY/OTHER PROCEDURES
Considered first line
- Cryotherapy: 5 to 10 seconds with 1- to 2-mm margins; repeat every 3 to 4 weeks as needed until lesions disappear (7)[B].
- Adverse effects: erythema, edema, pain, blistering
- Contraindications: cryoglobulinemia, Raynaud disease
- Curettage under local or topical anesthesia (1)[A],( 8)[B]
- Adverse effects: pain, scarring
COMPLEMENTARY & ALTERNATIVE MEDICINE
- Australian lemon myrtle oil: Apply 10% solution once daily for 21 days (9)[B].
- Potassium hydroxide 5 " 10% solution: Apply 1 to 2 times a day until the lesions disappeared completely (10)[B].
Pediatric Considerations
Pregnancy Considerations
Safe in pregnancy: curettage, cryotherapy, incision, and expression
ONGOING CARE
FOLLOW-UP RECOMMENDATIONS
Patient Monitoring
Depends on type of treatment
PATIENT EDUCATION
- Cover lesions to prevent spread.
- Avoid scratching.
- Avoid contact sports.
- Avoid sharing towels and clothing.
- Avoid sexual activity when lesions present.
PROGNOSIS
- Immunocompetent: self-limited, resolves in 3 to 12 months (range: 2 months to 4 years)
- Immunocompromised: lesions difficult to treat; may persist for years
COMPLICATIONS
- Secondary infection
- Scarring, hyper-/hypopigmentation
REFERENCES
11 van der Wouden JC, Menke J, Gajadin S, et al. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2006;(2):CD004767.22 Moye V, Cathcart S, Burkhart CN, et al. Beetle juice: a guide for the use of cantharidin in the treatment of molluscum contagiosum. Dermatol Ther. 2013;26(6):445 " 451.33 Silverberg NB, Sidbury R, Mancini AJ. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. J Am Acad Dermatol. 2000;43(3):503 " 507.44 Chen X, Anstey AV, Bugert JJ. Molluscum contagiosum virus infection. Lancet Infect Dis. 2013;13(10):877 " 888.55 Erikson C, Driscoll M, Gaspari A. Efficacy of intravenous cidofovir in the treatment of giant molluscum contagiosum in a patient with human immunodeficiency virus. Arch Dermatol. 2011;147(6):652 " 654.66 Javed S, Tyring SK. Treatment of molluscum contagiosum with ingenol mebutate. J Am Acad Dermatol. 2014;70(5):e105.77 Al-Mutairi N, Al-Doukhi A, Al-Farag S, et al. Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatr Dermatol. 2010;27(4):388 " 394.88 Hanna D, Hatami A, Powell J, et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatr Dermatol. 2006;23(6):574 " 579.99 Burke BE, Baillie JE, Olson RD. Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomed Pharmacother. 2004;58(4):245 " 247.1010 Can B, Topaloglu F, Kavlale M, et al. Treatment of pediatric molluscum contagiosum with 10% potassium hydroxide solution. J Dermatolog Treat. 2014;25(3):246 " 248.
ADDITIONAL READING
- Brown J, Janniger CK, Schwartz RA, et al. Childhood molluscum contagiosum. Int J Dermatol. 2006;45(2):93 " 99.
- Dohil MA, Lin P, Lee J, et al. The epidemiology of molluscum contagiosum in children. J Am Acad Dermatol. 2006;54(1):47 " 54.
- Olsen JR, Gallacher J, Piguet V, et al. Epidemiology of molluscum contagiosum in children: a systematic review. Fam Pract. 2014;31(2):130 " 136.
- Ting PT, Dytoc MT. Therapy of external anogenital warts and molluscum contagiosum: a literature review. Dermatol Ther. 2004;17(1):68 " 101.
CODES
ICD10
B08.1 Molluscum contagiosum
ICD9
078.0 Molluscum contagiosum
SNOMED
- 40070004 Molluscum contagiosum infection (disorder)
- 240467006 Genital molluscum contagiosum
- 397515005 Molluscum contagiosum blepharoconjunctivitis
- 314901000 Molluscum contagiosum with eyelid involvement (disorder)
CLINICAL PEARLS
- Natural resolution is preferred treatment in healthy patients.
- Reassure parents that lesions will heal naturally and generally resolve without scarring.
- No specific treatment has been identified as superior to any other.
- Consider topical corticosteroids for pruritus or associated dermatitis.